Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2017 | Pages:
118 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Ocular Hypertension - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ocular Hypertension - Pipeline Review, H1 2017, provides an overview of the Ocular Hypertension (Ophthalmology) pipeline landscape. Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal.� If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension.� There are no symptoms with ocular hypertension. Risk factors include age, family history of glaucoma, lower systemic blood pressure, thinner central cornea and bleeding at the optic nerve head. Treatment includes eye drops to reduce intraocular pressure. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ocular Hypertension - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Ocular Hypertension (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 8, 15, 2 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively. Ocular Hypertension (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Ocular Hypertension (Ophthalmology). - The pipeline guide reviews pipeline therapeutics for Ocular Hypertension (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Ocular Hypertension (Ophthalmology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Ocular Hypertension (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Ocular Hypertension (Ophthalmology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Ocular Hypertension (Ophthalmology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Ocular Hypertension (Ophthalmology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Ocular Hypertension - Overview Ocular Hypertension - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Ocular Hypertension - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Ocular Hypertension - Companies Involved in Therapeutics Development Aerie Pharmaceuticals Inc Allergan Plc Bausch & Lomb Inc Can-Fite BioPharma Ltd D. Western Therapeutics Institute Inc F. Hoffmann-La Roche Ltd Inotek Pharmaceuticals Corp Ironwood Pharmaceuticals Inc Laboratoires Thea SA Laboratorios Sophia SA de CV Lee's Pharmaceutical Holdings Ltd Lexicon Pharmaceuticals Inc Neurim Pharmaceuticals Ltd NicOx SA Ocular Therapeutix Inc Santen Pharmaceutical Co Ltd Senju Pharmaceutical Co Ltd Sylentis SAU ViSci Ltd Ocular Hypertension - Drug Profiles (bimatoprost + timolol maleate) - Drug Profile Product Description Mechanism Of Action R&D Progress (latanoprost + netarsudil mesylate) - Drug Profile Product Description Mechanism Of Action R&D Progress (latanoprost + timolol maleate) - Drug Profile Product Description Mechanism Of Action R&D Progress (latanoprost + trabodenoson) - Drug Profile Product Description Mechanism Of Action R&D Progress bamosiran - Drug Profile Product Description Mechanism Of Action R&D Progress bimatoprost - Drug Profile Product Description Mechanism Of Action R&D Progress bimatoprost SR - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy to Target Matrix Metalloproteinase 1 for Steroid Induced Glaucoma and Ocular Hypertension - Drug Profile Product Description Mechanism Of Action R&D Progress H-1129 - Drug Profile Product Description Mechanism Of Action R&D Progress IWP-953 - Drug Profile Product Description Mechanism Of Action R&D Progress latanoprost - Drug Profile Product Description Mechanism Of Action R&D Progress latanoprost SR - Drug Profile Product Description Mechanism Of Action R&D Progress latanoprost SR - Drug Profile Product Description Mechanism Of Action R&D Progress latanoprost SR - Drug Profile Product Description Mechanism Of Action R&D Progress latanoprostene bunod - Drug Profile Product Description Mechanism Of Action R&D Progress levobetaxolol hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress LX-7101 - Drug Profile Product Description Mechanism Of Action R&D Progress MGV-354 - Drug Profile Product Description Mechanism Of Action R&D Progress NCX-1653 - Drug Profile Product Description Mechanism Of Action R&D Progress NCX-470 - Drug Profile Product Description Mechanism Of Action R&D Progress NCX-667 - Drug Profile Product Description Mechanism Of Action R&D Progress netarsudil mesylate - Drug Profile Product Description Mechanism Of Action R&D Progress omidenepag isopropyl - Drug Profile Product Description Mechanism Of Action R&D Progress piclidenoson - Drug Profile Product Description Mechanism Of Action R&D Progress piromelatine - Drug Profile Product Description Mechanism Of Action R&D Progress PRO-067 - Drug Profile Product Description Mechanism Of Action R&D Progress RO-5093151 - Drug Profile Product Description Mechanism Of Action R&D Progress sepetaprost - Drug Profile Product Description Mechanism Of Action R&D Progress SNJ-1656 - Drug Profile Product Description Mechanism Of Action R&D Progress trabodenoson - Drug Profile Product Description Mechanism Of Action R&D Progress travoprost SR - Drug Profile Product Description Mechanism Of Action R&D Progress travoprost XR - Drug Profile Product Description Mechanism Of Action R&D Progress Ocular Hypertension - Dormant Projects Ocular Hypertension - Discontinued Products Ocular Hypertension - Product Development Milestones Featured News & Press Releases Feb 27, 2017: Bausch + Lomb And Nicox Resubmit US New Drug Application For Novel Glaucoma Candidate Latanoprostene Bunod Feb 21, 2017: Nicox announces the presentation of NCX 667 scientific data at AOPT 2017 Jan 24, 2017: Nicox provides clinical and regulatory update for NCX 470 for IOP lowering Jan 03, 2017: Inotek Announces Top-line Results for MATrX-1, First Phase 3 Trial of Trabodenoson for Glaucoma Dec 23, 2016: Aerie Pharmaceuticals Provides Update on Timing of NDA Filing for Rhopressa (netarsudil ophthalmic solution) 0.02% Dec 07, 2016: Aerie Pharmaceuticals Completes Enrollment of Mercury 2 Phase 3 Registration Trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Oct 27, 2016: Aerie Pharmaceuticals Reports Positive Topline Efficacy Results of Rocket 4 Phase 3 Trial of Rhopressa (netarsudil ophthalmic solution) 0.02% Oct 04, 2016: Ocular Therapeutix Begins Enrollment in First Phase 3 Clinical Trial with OTX-TP (Sustained Release Travoprost) for the Treatment of Glaucoma and Ocular Hypertension Sep 06, 2016: Aerie Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for Rhopressa (netarsudil ophthalmic solution) 0.02% Jul 22, 2016: Valeant Pharmaceuticals Receives Complete Response Letter From The FDA Jul 06, 2016: Bausch + Lomb and Nicox Announce the Publication of Latanoprostene Bunod Ophthalmic Solution 0.024% Phase 3 Study Results in American Journal of Ophthalmology Jun 16, 2016: Aerie Pharmaceuticals Completes Enrollment of Rocket 4 Phase 3 Clinical Trial of Rhopressa (netarsudil ophthalmic solution) 0.02% May 05, 2016: Aerie Pharmaceuticals Completes Enrollment of Mercury 1 Phase 3 Registration Trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Apr 27, 2016: Ocular Therapeutix Completes End-of-Phase 2 Review with FDA for OTX-TP (Sustained Release Travoprost) for Glaucoma and Ocular Hypertension Apr 26, 2016: Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Ocular Hypertension, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Ocular Hypertension - Pipeline by Aerie Pharmaceuticals Inc, H1 2017 Ocular Hypertension - Pipeline by Allergan Plc, H1 2017 Ocular Hypertension - Pipeline by Bausch & Lomb Inc, H1 2017 Ocular Hypertension - Pipeline by Can-Fite BioPharma Ltd, H1 2017 Ocular Hypertension - Pipeline by D. Western Therapeutics Institute Inc, H1 2017 Ocular Hypertension - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 Ocular Hypertension - Pipeline by Inotek Pharmaceuticals Corp, H1 2017 Ocular Hypertension - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017 Ocular Hypertension - Pipeline by Laboratoires Thea SA, H1 2017 Ocular Hypertension - Pipeline by Laboratorios Sophia SA de CV, H1 2017 Ocular Hypertension - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017 Ocular Hypertension - Pipeline by Lexicon Pharmaceuticals Inc, H1 2017 Ocular Hypertension - Pipeline by Neurim Pharmaceuticals Ltd, H1 2017 Ocular Hypertension - Pipeline by NicOx SA, H1 2017 Ocular Hypertension - Pipeline by Ocular Therapeutix Inc, H1 2017 Ocular Hypertension - Pipeline by Santen Pharmaceutical Co Ltd, H1 2017 Ocular Hypertension - Pipeline by Senju Pharmaceutical Co Ltd, H1 2017 Ocular Hypertension - Pipeline by Sylentis SAU, H1 2017 Ocular Hypertension - Pipeline by ViSci Ltd, H1 2017 Ocular Hypertension - Dormant Projects, H1 2017 Ocular Hypertension - Dormant Projects, H1 2017 (Contd..1), H1 2017 Ocular Hypertension - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
